Correspondingly, screening for overexpression of these factors might lead to early identification of ER+ breast cancer patients at risk for endocrine resistance and help to devise the most suitable therapeutic approaches to minimize the risk and optimize the effectiveness of anticancer treatment. Here, ESR1 is linked to breast carcinoma.